Nelson Alexandre Kretzmann, Eduardo Chiela, Ursula Matte, Norma Marroni, Claudio Augusto Marroni
{"title":"n -乙酰半胱氨酸通过下调肝癌细胞NF-kB来改善干扰素α的抗肿瘤反应。","authors":"Nelson Alexandre Kretzmann, Eduardo Chiela, Ursula Matte, Norma Marroni, Claudio Augusto Marroni","doi":"10.1186/1476-5926-11-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Unlabelled: </strong></p><p><strong>Background: </strong>Liver cancer is one of the most common malignancies in the world and at the moment, there is no drug intervention effective for the treatment of liver tumours. Investigate the effect of N-acetylcysteine (NAC), which has been studied for its antitumoural properties, on the toxicity of hepatocarcinoma (HCC) cells in vitro when used with the drug interferon alpha-2A (IFN), which is used clinically to treat HCC.</p><p><strong>Results: </strong>NAC, IFN and NAC plus IFN reduced cell viability, as determined by MTT assay. More importantly, NAC potentiates the cytotoxic effect of IFN, with the best response achieved with 10 mM of NAC and 2.5 x 104 of IFN. These results were confirmed by Annexin/PI staining through flow cytometry and morphologic analyses. Co-treatment reduced the expression of the nuclear transcription factor kappa-B (NF-kB). In a similar way to NAC, RNAi against p65 potentiated the toxic effect of IFN, suggesting that, indeed, NAC may be enhancing the effect of IFN through inhibition of NF-kB.</p><p><strong>Conclusions: </strong>Our results support the notion that NAC may be an important drug for the treatment of liver tumours as primary or adjuvant therapy. IFN has a limited clinical response, and therefore, the anti-proliferative properties of NAC in the liver should be explored further as an alternative for non-responders to IFN treatment.</p>","PeriodicalId":84474,"journal":{"name":"Comparative hepatology","volume":"11 1","pages":"4"},"PeriodicalIF":0.0000,"publicationDate":"2012-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1476-5926-11-4","citationCount":"33","resultStr":"{\"title\":\"N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells.\",\"authors\":\"Nelson Alexandre Kretzmann, Eduardo Chiela, Ursula Matte, Norma Marroni, Claudio Augusto Marroni\",\"doi\":\"10.1186/1476-5926-11-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Unlabelled: </strong></p><p><strong>Background: </strong>Liver cancer is one of the most common malignancies in the world and at the moment, there is no drug intervention effective for the treatment of liver tumours. Investigate the effect of N-acetylcysteine (NAC), which has been studied for its antitumoural properties, on the toxicity of hepatocarcinoma (HCC) cells in vitro when used with the drug interferon alpha-2A (IFN), which is used clinically to treat HCC.</p><p><strong>Results: </strong>NAC, IFN and NAC plus IFN reduced cell viability, as determined by MTT assay. More importantly, NAC potentiates the cytotoxic effect of IFN, with the best response achieved with 10 mM of NAC and 2.5 x 104 of IFN. These results were confirmed by Annexin/PI staining through flow cytometry and morphologic analyses. Co-treatment reduced the expression of the nuclear transcription factor kappa-B (NF-kB). In a similar way to NAC, RNAi against p65 potentiated the toxic effect of IFN, suggesting that, indeed, NAC may be enhancing the effect of IFN through inhibition of NF-kB.</p><p><strong>Conclusions: </strong>Our results support the notion that NAC may be an important drug for the treatment of liver tumours as primary or adjuvant therapy. IFN has a limited clinical response, and therefore, the anti-proliferative properties of NAC in the liver should be explored further as an alternative for non-responders to IFN treatment.</p>\",\"PeriodicalId\":84474,\"journal\":{\"name\":\"Comparative hepatology\",\"volume\":\"11 1\",\"pages\":\"4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-12-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/1476-5926-11-4\",\"citationCount\":\"33\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Comparative hepatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/1476-5926-11-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Comparative hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1476-5926-11-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 33
摘要
背景:肝癌是世界上最常见的恶性肿瘤之一,目前还没有有效的药物干预治疗肝肿瘤。研究n -乙酰半胱氨酸(NAC)在体外与临床上用于治疗HCC的药物干扰素α - 2a (IFN)联合使用时对肝癌(HCC)细胞毒性的影响,NAC已被研究具有抗肿瘤特性。结果:MTT法检测NAC、IFN及NAC + IFN均降低细胞活力。更重要的是,NAC增强了IFN的细胞毒性作用,10 mM NAC和2.5 × 104 IFN达到最佳效果。通过流式细胞术和形态学分析,Annexin/PI染色证实了上述结果。共处理降低了核转录因子κ b (NF-kB)的表达。与NAC类似,针对p65的RNAi增强了IFN的毒性作用,这表明NAC确实可能通过抑制NF-kB来增强IFN的作用。结论:我们的研究结果支持NAC可能作为主要或辅助治疗肝肿瘤的重要药物的观点。IFN的临床反应有限,因此,肝脏NAC的抗增殖特性应进一步探索,作为对IFN治疗无反应的替代方案。
N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells.
Unlabelled:
Background: Liver cancer is one of the most common malignancies in the world and at the moment, there is no drug intervention effective for the treatment of liver tumours. Investigate the effect of N-acetylcysteine (NAC), which has been studied for its antitumoural properties, on the toxicity of hepatocarcinoma (HCC) cells in vitro when used with the drug interferon alpha-2A (IFN), which is used clinically to treat HCC.
Results: NAC, IFN and NAC plus IFN reduced cell viability, as determined by MTT assay. More importantly, NAC potentiates the cytotoxic effect of IFN, with the best response achieved with 10 mM of NAC and 2.5 x 104 of IFN. These results were confirmed by Annexin/PI staining through flow cytometry and morphologic analyses. Co-treatment reduced the expression of the nuclear transcription factor kappa-B (NF-kB). In a similar way to NAC, RNAi against p65 potentiated the toxic effect of IFN, suggesting that, indeed, NAC may be enhancing the effect of IFN through inhibition of NF-kB.
Conclusions: Our results support the notion that NAC may be an important drug for the treatment of liver tumours as primary or adjuvant therapy. IFN has a limited clinical response, and therefore, the anti-proliferative properties of NAC in the liver should be explored further as an alternative for non-responders to IFN treatment.